Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations

Open Access

Peer-reviewed

Research Article

Christian Callebaut ,

* E-mail: christian.callebaut@gilead.com

Affiliation Clinical Virology Department, Gilead Sciences, Foster City, California, United States of America
⨯
Yang Liu,

Affiliation Clinical Virology Department, Gilead Sciences, Foster City, California, United States of America
⨯
Darius Babusis,

Affiliation Drug Metabolism Department, Gilead Sciences, Foster City, California, United States of America
⨯
Adrian Ray,

Affiliation Drug Metabolism Department, Gilead Sciences, Foster City, California, United States of America
⨯
Michael Miller,

Affiliation Clinical Virology Department, Gilead Sciences, Foster City, California, United States of America
⨯
Kathryn Kitrinos

Affiliation Clinical Virology Department, Gilead Sciences, Foster City, California, United States of America
⨯

Reader Comments (0)

Osteoblasts
Is the Subject Area "Osteoblasts" applicable to this article?

Thanks for your feedback.
Bone density
Is the Subject Area "Bone density" applicable to this article?

Thanks for your feedback.
Drug therapy
Is the Subject Area "Drug therapy" applicable to this article?

Thanks for your feedback.
Oils
Is the Subject Area "Oils" applicable to this article?

Thanks for your feedback.
HIV-1
Is the Subject Area "HIV-1" applicable to this article?

Thanks for your feedback.
Antiretroviral therapy
Is the Subject Area "Antiretroviral therapy" applicable to this article?

Thanks for your feedback.
Blood plasma
Is the Subject Area "Blood plasma" applicable to this article?

Thanks for your feedback.
Phosphates
Is the Subject Area "Phosphates" applicable to this article?

Thanks for your feedback.